Merck to Acquire Rigontec, Expanding Cancer Immunotherapy Franchise – Genetic Engineering & Biotechnology News
Labiotech.eu |
Merck to Acquire Rigontec, Expanding Cancer Immunotherapy Franchise
Genetic Engineering & Biotechnology News Merck & Co. has agreed to acquire Rigontec for up to €464 million (about $554 million), in a deal that will expand the cancer immunotherapy franchise of the Keytruda® (pembrolizumab) developer with a three-year-old Bonn University spinout whose … Merck, looking to build on cancer success, buys IO biotech Rigontec Merck To Buy Rigontec MSD to Acquire Rigontec, RIG-I Therapeutics Pioneer, Advancing Leadership in Immuno-Oncology |
